Moffitt Cancer Center Partners with Japan’s CMIC for Global Cancer Trials

• Moffitt Cancer Center has partnered with Japan’s largest contract research organization (CRO), CMIC, to enhance global cancer trial capabilities.

• The partnership will allow Moffitt to serve as the primary U.S. site for CMIC’s trials while CMIC will manage Moffitt’s trials in Japan and the Asia-Pacific region.

Moffitt Cancer Center, a Comprehensive Cancer Center designated by the National Cancer Institute, announced its collaboration with CMIC. The partnership aims to facilitate cross-border clinical trials for new therapies, increasing participant diversity.

Under the agreement, Moffitt will act as the go-to U.S. location for CMIC’s trials. In return, CMIC will assist in managing Moffitt’s trials in Japan and throughout the Asia-Pacific region. This collaboration is expected to streamline the process of running international cancer trials, making them more efficient.

Xavier Avat, Moffitt’s chief business officer, stated, “This partnership allows us to significantly expand the portfolio of cutting-edge clinical trials available to our patients while providing easy and rapid access for CMIC customers who need a U.S. site for clinical trials.”

CMIC, recognised as Japan’s first and largest CRO, operates in 12 countries, including Australia, China, South Korea, and Taiwan. This partnership follows CMIC’s previous U.S. collaboration with Rutgers University to establish a pharmaceutical production facility in New Jersey.